ISRCTN10125877已完成不适用
A Phase II study of pazopanib in metastatic merkel cell carcinoma
niversity of Birmingham (UK)0 个研究点目标入组 25 人开始时间: 2013年3月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 17/01/2014:
- •1. Patients with histologically proven, unresectable, MCC that is metastatic and/or for which durable control cannot be achieved with surgery or radiotherapy
- •2. RECIST measurable disease, as per RECIST version 1.1
- •3. Age =18 years, either sex
- •4. Performance status 0, 1 or 2 assessed using the Eastern Cooperative Oncology Group scale
- •5. Received previous first line chemotherapy or considered unsuitable for chemotherapy
- •6. Toxicities from first line chemotherapy resolved to at least grade 1
- •7. Adequate end organ function
- •7.1. Renal function tests: serum creatinine =150 µmol/L. If serum creatinine is >150 µmol/L, calculated creatinine clearance must be =30 ml/min Urine Protein to Creatinine ratio (UPC) <1. If UPC =1, then a 24-hour protein must be assessed. Patients must have 24-hour protein value <1 g to be eligible. Alternatively, Albumin/Creatinine ratio may be measured (in accordance with institutional policy, same test to be used for study duration)
- •7.2. Liver function tests: Total serum bilirubin =1.5 X Upper Limit Normal (ULN), Alanine Aminotransferase or Aspartate Aminotransferase (in accordance with institutional policy, same test to be used for study duration) =2.5 X ULN (or =5 X ULN if liver metastases are present)
- •7.3. Haematology: Absolute Neutrophil Count (ANC) =1.5 X 109/L, Serum creatinine =150 µmol/L. If serum creatinine >150 µmol/L, calculated creatinine clearance must be =30 ml/min, Urine Protein to Creatinine ratio (UPC) <1. If UPC =1, then a 24-hour protein must be assessed. Patients must have 24hour protein value <1 g to be eligible
- •7.4. Liver function tests: Total serum bilirubin =1.5 X Upper Limit Normal (ULN), Alanine Aminotransferase or Aspartate Aminotransferase (in accordance with institutional policy, same test to be used for study duration) =2.5 X ULN (or =5 X ULN if liver metastases are present)
- •7.5. Haematology: Absolute Neutrophil Count (ANC) =1.5 X 109/L Haemoglobin =10 g/dL Platelets =100 X 10 to the power of 9/L
- •7.6. Coagulation test: International Normalized Ratio =1.2 X ULN, unless on therapeutic anticoagulation. For patients on therapeutic anticoagulation, INR should be stable and in target range
- •8. Able to give written informed consent
- •9. Women of childbearing potential, or men in a relationship with a woman of childbearing age, prepared to adopt adequate contraceptive measures if sexually active
- •10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
- •Previous inclusion criteria:
- •1. Patients with histologically proven, unresectable, MCC that is metastatic and/or for which durable control cannot be achieved with surgery or radiotherapy
- •2. RECIST measurable disease, as per RECIST version 1.1
- •3. Age =18 years, either sex
- •4. Performance status 0, 1 or 2 assessed using the Eastern Cooperative Oncology Group scale
- •5. Received previous first line chemotherapy or considered unsuitable for chemotherapy
- •6. Toxicities from first line chemotherapy resolved to at least grade 1
- •7. Adequate end organ function
- •7.1. Renal function tests: Serum creatinine =150 µmol/L. If serum creatinine >150 µmol/L, calculated creatinine clearance must be =30 ml/min Urine Protein to Creatinine ratio (UPC) <1. If UPC =1, then a 24-hour protein must be assessed. Patients must have 24-hour protein value <1 g to be eligible
- •7.2. Liver function tests: Total serum bilirubin =1.5 X Upper Limit Normal (ULN), Alanine Aminotrans
排除标准
- •1. Previous malignancies. (Unless agreed in writing by the Chief Investigator or a clinical Coinvestigator, investigators are advised to call the Trial Office).
- •2. Known brain metastases unless radically treated with surgery or radiotherapy >6 months prior to study entry and without evidence of central nervous system progression since treatment
- •3. History in the past 6 months of cerebral or clinically significant gastrointestinal haemorrhage
- •4. Haemoptysis within 6 weeks prior to first dose of study medication
- •5. Evidence of active bleeding or bleeding diathesis
- •6. Uncontrolled hypertension defined as systolic blood pressure =140 mm Hg or diastolic blood pressure =90 mm Hg. Initiation or adjustment of antihypertensive medication(s) is permitted prior to trial entry
- •7. Presence of uncontrolled infection
- •8. History of malabsorption, major gastrointestinal tract resection or other pathology likely to affect absorption of study medication
- •9. Prolongation of the QT interval (QTc) >480 milliseconds
- •10. History of any one or more of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III or IV congestive heart failure, as defined by the New York Heart Association Functional Classification
- •11. History of cerebrovascular accident including transient ischemic attack within the past 12 months
- •12. History of pulmonary embolism or untreated deep venous thrombosis within the past 6 months. Patients with a history of thromboembolic disease who are on treatment with therapeutic anticoagulating agents are eligible
- •13. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
- •14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drug chemically related to pazopanib
- •15. Major surgery or trauma <4 weeks prior to starting study medication and/or presence of any nonhealing wound, fracture, or ulcer
- •16. Radiotherapy <2 weeks prior to starting study medication
- •17. Known HIV, Hepatitis B or C infection
- •18. Pregnant (female patients of child bearing potential should have a urine or blood Human Chorionic Gonadotropin test performed to rule out pregnancy prior to trial entry)
- •19. Lactating females. Patients who agree to discontinue nursing 14 days prior to commencing treatment and do not nurse throughout all the treatment period are eligible
- •20. The use of the following medication is prohibited: Previous therapy with agents that target the Vascular Endothelial Growth Factor (VEGF) or Platelet derived Growth Factor (PDGF) pathways Chemotherapy, immunotherapy, biologic therapy, investigational therapy, hormone therapy or use of any prohibited medications within 14 days prior to the first dose of study medication Use of drugs which are known strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose of study medication
- •21. Any serious and/or unstable preexisting medical, psychiatric, or other conditions that could interfere with patient?s safety, obtaining informed consent or compliance to the study
- •22. Other contraindications to study medication
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma (called UKMCC-01)EUCTR2011-003226-27-GBniversity of Birmingham
进行中（未招募）
1 期
A trial to examine the effect of pazopanib on survival in patients with metastatic renal cell cancer who have already received and relapsed on, or did not tolerate sunitinib treatmentMetastatic or unresectable renal cell carcinomaMedDRA version: 21.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022770-13-IECancer Trials Ireland48
进行中（未招募）
1 期
A trial to examine the effect of pazopanib on survival in patients with metastatic renal cell cancer who have already received and relapsed on, or did not tolerate sunitinib treatmentEUCTR2010-022770-13-SEICORG- All Ireland Co-operative Oncology Research Group48
尚未招募
2 期
Cabozantinib in Advanced Gastrointestinal Stromal TumorCTRI/2024/06/068636I
进行中（未招募）
1 期
A study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma.Surgically unresectable or metastatic chondrosarcomaEUCTR2013-004851-19-GBACORN Research, LLC47